Samuel Rosas1,2, Karim Sabeh3, Jennifer Kurowicki2,4, Leonard Buller3, Tsun Yee Law2, Martin Roche2, Sheila Conway3, Victor H Hernandez3. 1. Department of Orthopedic Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA. 2. Department of Orthopedic Surgery, Holy Cross Hospital, Fort Lauderdale, FL, USA. 3. Department of Orthopedic Surgery and Rehabilitation, University of Miami, Miami, FL, USA. 4. Department of Orthopaedic Surgery, School of Health and Medical Sciences, Seton Hall University, South Orange, NJ, USA.
Abstract
BACKGROUND: Total hip arthroplasty (THA) is a common and growing procedure in the United States. Concomitantly, there has been a rise in patients diagnosed with certain types of malignancies including solid organ ones. Unfortunately there is limited data available in the literature that describes the use of THA in patients who concomitantly have one of these forms of cancer. Because of the limited data available in the literature regarding this topic, the purpose of this study was to analyze the trends in use of THA among patients with the five most common malignancies in the United States, which include breast, lung, prostate, colon and bladder cancer according to the National Cancer Institute (NCI). METHODS: We conducted a retrospective review of the entire Medicare patient population to analyze the use of THA in patients with a diagnosis of solid organ malignancy including breast, lung, prostate, colon and bladder cancer. RESULTS: Our analysis of over 14 million patients, demonstrate that THA is not as commonly performed procedure in patients with such diagnoses with a 0.26% prevalence. The mean incidence of THA was 0.29%, 0.17%, 0.31%, 0.33% and 0.36% for patients with breast, lung, prostate, colon and bladder cancer respectively. CONCLUSIONS: THA in cancer patients are not frequently performed but the use of this technique has increased significantly in patients with lung, prostate and bladder cancer.
BACKGROUND: Total hip arthroplasty (THA) is a common and growing procedure in the United States. Concomitantly, there has been a rise in patients diagnosed with certain types of malignancies including solid organ ones. Unfortunately there is limited data available in the literature that describes the use of THA in patients who concomitantly have one of these forms of cancer. Because of the limited data available in the literature regarding this topic, the purpose of this study was to analyze the trends in use of THA among patients with the five most common malignancies in the United States, which include breast, lung, prostate, colon and bladder cancer according to the National Cancer Institute (NCI). METHODS: We conducted a retrospective review of the entire Medicare patient population to analyze the use of THA in patients with a diagnosis of solid organ malignancy including breast, lung, prostate, colon and bladder cancer. RESULTS: Our analysis of over 14 million patients, demonstrate that THA is not as commonly performed procedure in patients with such diagnoses with a 0.26% prevalence. The mean incidence of THA was 0.29%, 0.17%, 0.31%, 0.33% and 0.36% for patients with breast, lung, prostate, colon and bladder cancer respectively. CONCLUSIONS: THA in cancer patients are not frequently performed but the use of this technique has increased significantly in patients with lung, prostate and bladder cancer.
Entities:
Keywords:
Total hip arthroplasty (THA); bladder cancer; breast cancer; lung cancer; prostate cancer; utilization
Authors: Steven Kurtz; Fionna Mowat; Kevin Ong; Nathan Chan; Edmund Lau; Michael Halpern Journal: J Bone Joint Surg Am Date: 2005-07 Impact factor: 5.284
Authors: Jennifer Elston Lafata; Jan Simpkins; Lonni Schultz; Gary A Chase; Christine Cole Johnson; Marianne Ulcickas Yood; Lois Lamerato; David Nathanson; Greg Cooper Journal: Med Care Date: 2005-06 Impact factor: 2.983
Authors: Carlos B Mantilla; C Thomas Wass; Karissa A Goodrich; Cassie J Johanns; Michelle L Kool; Xun Zhu; Jose A Corredor; David O Warner; Michael J Joyner; Daniel J Berry; Darrell R Schroeder; Juraj Sprung Journal: Transfusion Date: 2011-01 Impact factor: 3.157
Authors: Michaela M Schneiderbauer; Marius von Knoch; Cathy D Schleck; William S Harmsen; Franklin H Sim; Sean P Scully Journal: J Bone Joint Surg Am Date: 2004-08 Impact factor: 5.284